CDAK Codiak BioSciences, Inc. Stock Quote

CDAK [NASD]

Index	-	P/E	-	EPS (ttm)	-1.05	Insider Own	0.10%	Shs Outstand	97.52M	Perf Week	-16.85%
Market Cap	292.76M	Forward P/E	-	EPS next Y	-3.81	Insider Trans	26.50%	Shs Float	19.20M	Perf Month	-28.68%
Income	-102.50M	PEG	-	EPS next Q	-1.09	Inst Own	62.50%	Short Float	3.27%	Perf Quarter	-56.68%
Sales	2.90M	P/S	100.95	EPS this Y	-31.50%	Inst Trans	-	Short Ratio	4.40	Perf Half Y	6.27%
Book/sh	0.15	P/B	85.87	EPS next Y	9.50%	ROA	-84.00%	Target Price	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	60.10%	52W Range	7.90 - 37.85	Perf YTD	-60.12%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-229.60%	52W High	-65.97%	Beta	-
Dividend %	-	Quick Ratio	5.30	Sales past 5Y	-	Gross Margin	-	52W Low	63.04%	ATR	1.50
Employees	105	Current Ratio	5.30	Sales Q/Q	700.00%	Oper. Margin	-	RSI (14)	37.57	Volatility	9.97% 10.32%
Optionable	No	Debt/Eq	1.71	EPS Q/Q	23.30%	Profit Margin	-	Rel Volume	0.53	Prev Close	13.31
Shortable	Yes	LT Debt/Eq	1.71	Earnings	-	Payout	-	Avg Volume	142.54K	Price	12.88
Recom	1.50	SMA20	-13.32%	SMA50	-27.29%	SMA200	-26.07%	Volume	75,076	Change	-3.23%

Nov-09-20

Initiated

Wedbush

Outperform

$19

Nov-09-20

Initiated

Goldman

Buy

$29

Apr-10-21 08:30AM	Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy Pathways GlobeNewswire
Mar-30-21 09:30AM	Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer PR Newswire
Mar-17-21 07:30AM	Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress GlobeNewswire
Mar-10-21 04:38PM	Codiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidate Programs at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Feb-20-21 01:27AM	Independent Director Briggs Morrison Just Bought A Handful Of Shares In Codiak BioSciences, Inc. (NASDAQ:CDAK) Simply Wall St.
Feb-17-21 04:30PM	Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters Option GlobeNewswire -7.93%
Feb-11-21 10:18PM	Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock GlobeNewswire
Feb-09-21 04:17PM	Codiak Announces Proposed Public Offering of Common Stock GlobeNewswire -8.83%
Feb-04-21 07:30AM	Codiak Reports Additional Positive Phase 1 Results for exoIL-12 Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients GlobeNewswire
Jan-21-21 09:00AM	Codiaks Versatile engEx Platform for Engineered Exosomes Published in the Journal Molecular Therapy GlobeNewswire -5.41%
Jan-13-21 11:58PM	What Percentage Of Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares Do Insiders Own? Simply Wall St. +12.36%
Dec-30-20 07:00AM	Codiak Reports Positive Initial Phase 1 Results for exoIL-12 Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers GlobeNewswire +29.15%
Dec-21-20 09:00AM	New Publication in Molecular Cancer Therapeutics Highlights Data from Preclinical Development of exoIL-12 for the Treatment of Cancer GlobeNewswire +19.46%
Nov-27-20 11:55AM	Goldman Sachs: These 3 Stocks Could Spike Over 40% TipRanks +6.78%
Nov-23-20 07:30AM	Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire +7.01%
Nov-19-20 04:05PM	Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress GlobeNewswire
Nov-09-20 08:00AM	Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity GlobeNewswire
Oct-23-20 06:00PM	Foghorn Therapeutics, the Latest Biotech to Go Public, Rises 13% in Its Market Debut Barrons.com
Oct-13-20 07:04PM	Codiak Announces Pricing of Initial Public Offering Business Wire

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morrison Briggs	Director	Feb 17	Buy	21.00	4,761	99,981	4,761	Feb 17 06:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience